Can bispecifics succeed where ADCs have failed?
This post is a consideration of a novel target and the promise, opportunities, and lessons learned from recent translational research as well as early phase clinical trials.
In exploring different modalities – can we expect to see different results?
Several companies have attempted to therapeutically drug this target with an array of agents, including ADCs, antibodies, vaccines, and even CAR-T cell therapy, raising the critical question of whether bispecifics can succeed where ADCs and others have failed?
Where does this target now stand from both a new product development and BD&L perspective?
Like fantasy football, if you have it in your portfolio, should you play it, bench it, waive it or trade it for something else?
In this case study, we’re offering our analysis, commentary, and conclusions…
BSB subscribers can read up on our ongoing commentary and analysis from the cancer conference season – you can either log-in or click to access our latest analysis.
This content is restricted to subscribers
